MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
Microviable Therapeutics expands leadership team with Chief Financial Officer
Gijón, Spain, September 23rd 2024 – Microviable Therapeutics, a biotech company developing novel biological drugs [...]
World Cancer Research Day: Exploring Microbiome-Based Cancer Therapies
On September 24th, we join the global community in recognizing World Cancer Research Day (WCRD)—an [...]
David Ríos Covián will participate in the 24th Drug Discovery Innovation Programme
David Ríos Covián, Director of Technology Development at Microviable Therapeutics, will participate in the 24th [...]
CONTACT
Get in touch with us for any questions using the following contact form.